Clinical trials: Papillary Thyroid Carcinoma
Papillary Thyroid Carcinoma
Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy
The robotic thyroidectomy (RT) has excellent cosmetic and several functional results. But there were no definite evidence of oncological safety of robotic thyroidectomy yet.
- Trial name
- NCT01354639
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Yonsei University
Papillary Thyroid Cancer
Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma
BRAFV600E is the most frequent oncogene in Papillary thyroid carcinoma (PTC). It correlates with greater extension, lymph node metastasis, and advanced stage.
- Trial name
- ABOUT (NCT04664413)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Salerno
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Papillary Thyroid Microcarcinoma
Radiofrequency Ablation Treatment of Low-Risk Papillary Thyroid Carcinomas
Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefully selected low-risk papillary thyroid microcarcinoma patient group.
- Trial name
- NCT07506161
- Testing
- Radiofrequency ablation alone
- Where
- Hungary
- Volunteers
- 27 people
- Sponsor
- Premier G Med Cardio Kft
Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer.
- Conditions
- Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01208051
- Testing
- Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 33 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- National Cancer Institute (NCI)